



TORPEDO-CF



Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis

Recent research shows a combination of drugs could improve lung function in some patients with CF



A recent clinical trial has shown that using a combination of two drugs, Iva-caftor and Lumacaftor in patients with CF can lead to an improvement in lung function and reduction in pulmonary exacerbations.

The trial was conducted in North America, Europe and Australia and included a total of 1,108 patients aged 12 years and older. All trial participants had two copies of the Phe508del mutation which is the most common type of mutation of the cystic fibrosis trans-membrane conductance regulator (CFTR) gene.

The purpose of the combination therapy is to improve the function of a malfunctioning protein caused by the faulty CFTR gene.

The trial showed that the combination therapy can lead to an improvement in lung function by an average of 2.6–4.0% and there was also a marked reduction in pulmonary exacerbations by 30-39%. Read more details about the trial in the New England Journal of Medicine or, if reading this newsletter online by clicking [here](#).

Vertex, the manufacturers of the drugs are applying for a license to sell the combination therapy in the EU. It is anticipated a decision will be made in the autumn.

Contact Us

If you would like more information about the trial please either speak to your clinical team at site or contact us by email or via our website:

www.torpedo-cf.org.uk
torpedo@liverpool.ac.uk



Second UK CF research meeting scheduled for November 2015

Date of Meeting:

Friday 13th November 2015

Purpose of the meeting:

- To review progress with CF clinical trials in the UK
- To highlight barriers to recruitment and successful strategies to overcome them


We are hoping to stream the meeting live over the internet for you to watch or download afterwards.

We are also investigating the possibility of involving CF patients and their families in the meeting via online submission of questions that will then be answered by a panel of experts during the meeting.

Further details about the meeting and how to get involved will be available via the trial website in the autumn.

TORPEDO-CF recruitment:

As of July 2015 we have achieved **80%** of our recruitment target of 280!



Thank you for taking the time to read this newsletter.